# A Multinational Phase III Study of CS-8958 (MARVEL)

> **NCT00803595** · PHASE3 · COMPLETED · sponsor: **Daiichi Sankyo Co., Ltd.** · enrollment: 1002 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **DRUG:** CS-8958
- **DRUG:** CS-8958
- **DRUG:** oseltamivir phosphate

## Key facts

- **NCT ID:** NCT00803595
- **Lead sponsor:** Daiichi Sankyo Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2009-03
- **Final completion:** 2009-06
- **Target enrollment:** 1002 (ACTUAL)
- **Last updated:** 2019-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00803595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00803595, "A Multinational Phase III Study of CS-8958 (MARVEL)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00803595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*